Rare Cancers: Medical Treatments
Commons · Question 116002 · Tabled 25 Feb 2026 · Department of Health and Social Care · Official record
Answered 4 Mar 2026
Question
Asked by Clive Jones
To ask the Secretary of State for Health and Social Care, whether the joint accelerated approvals pathway operated by the National Institute for Health and Care Excellence and Medicines and Healthcare products Regulatory Agency will enable tumour-agnostic
Answer
Answered by Zubir Ahmed, 4 Mar 2026
The Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) are working to deliver the Government’s ambitions, as set out in the 10-Year Health Plan for England and the Life Sciences Sect...